Home
/
Eton Pharmaceuticals, Inc.
/
Financials
/
Quarterly
Eton Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Eton Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$22.46M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$18.93M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$17.28M
May 13, 2025
Q3
2025
Sep 30, 2024
$10.32M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$9.07M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$7.97M
May 13, 2025
Q3
2024
Sep 30, 2023
$7.03M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$12.00M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$5.30M
May 9, 2024
Q3
2023
Sep 30, 2022
$3.22M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$7.36M
Aug 10, 2023
Q1
2023
Mar 31, 2022
$2.18M
May 11, 2023
Q3
2022
Sep 30, 2021
$775.0K
Nov 10, 2022
Q2
2022
Jun 30, 2021
$3.07M
Aug 11, 2022
Q1
2022
Mar 31, 2021
$11.90M
May 12, 2022
Q3
2021
Sep 30, 2020
($161.0K)
Nov 16, 2021
Q2
2021
Jun 30, 2020
$20.0K
Aug 16, 2021
Q1
2021
Mar 31, 2020
$99.0K
May 13, 2021
Q3
2020
Sep 30, 2019
$500.0K
Nov 12, 2020
Q2
2020
Jun 30, 2019
$500.0K
Aug 12, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.93M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($2.59M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($1.57M)
May 13, 2025
Q3
2025
Sep 30, 2024
$627.0K
Nov 6, 2025
Q2
2025
Jun 30, 2024
($3.04M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($811.0K)
May 13, 2025
Q3
2024
Sep 30, 2023
($579.0K)
Nov 12, 2024
Q2
2024
Jun 30, 2023
$4.56M
Aug 8, 2024
Q1
2024
Mar 31, 2023
($2.66M)
May 9, 2024
Q3
2023
Sep 30, 2022
($3.05M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($1.56M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($5.33M)
May 11, 2023
Q3
2022
Sep 30, 2021
($6.09M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($2.02M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
$5.12M
May 12, 2022
Q3
2021
Sep 30, 2020
($6.50M)
Nov 16, 2021
Q2
2021
Jun 30, 2020
($4.73M)
Aug 16, 2021
Q1
2021
Mar 31, 2020
($9.05M)
May 13, 2021
Q3
2020
Sep 30, 2019
($4.97M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($3.25M)
Aug 12, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.36M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($1.48M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($470.0K)
May 13, 2025
Q3
2025
Sep 30, 2024
$509.0K
Nov 6, 2025
Q2
2025
Jun 30, 2024
($2.94M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($800.0K)
May 13, 2025
Q3
2024
Sep 30, 2023
($548.0K)
Nov 12, 2024
Q2
2024
Jun 30, 2023
$3.88M
Aug 8, 2024
Q1
2024
Mar 31, 2023
($2.53M)
May 9, 2024
Q3
2023
Sep 30, 2022
($2.90M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($1.34M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($5.09M)
May 11, 2023
Q3
2022
Sep 30, 2021
($5.85M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($2.33M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
$5.36M
May 12, 2022
Q3
2021
Sep 30, 2020
($6.27M)
Nov 16, 2021
Q2
2021
Jun 30, 2020
($4.54M)
Aug 16, 2021
Q1
2021
Mar 31, 2020
($8.88M)
May 13, 2021
Q3
2020
Sep 30, 2019
($5.04M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($3.35M)
Aug 12, 2020